In 2009, the National Eye Institute (NEI) and the US Food and Drug Administration recommended using patient-reported outcomes (PROs) in clinical trials evaluating ophthalmic drugs and devices.1 For glaucoma, clinical practice traditionally does not use PROs but uses measures, such as intraocular pressure reduction and visual field (VF) loss, to monitor the effect of intervention and disease progression. However, there is an increasing recognition that PROs are valuable tools for assessing the way a disease or treatment affects a patient’s functions—information that clinical measures, such as VF or intraocular pressure, may not capture. Instruments such as the 25-item NEI Visual Function Questionnaire (NEI VFQ-25) have been validated and proven useful as PROs in clinical trials of patients with glaucoma. In clinical practice, clinicians can use PROs to monitor changes or responses to treatment, prioritize health problems, facilitate patient-clinician communication, and identify patient treatment preferences.
Varma R, Jiang X. Use of Structural End Points in Glaucoma: Beyond Visual Field Loss. JAMA Ophthalmol. 2017;135(7):789–790. doi:10.1001/jamaophthalmol.2017.1657
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: